Drug Trial Radar · NCT03888066
Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure (DIAMOND)
Last checked: Nov 20, 2026Latest source record: Feb 24, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,195
Actual
Start
Apr 24, 2019
Primary completion
Sep 2, 2021
Study completion Sep 2, 2021
Sponsor
- Lead sponsor
- Vifor Pharma, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Syneos Health
- First posted
- Mar 25, 2019
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to assess the effects of patiromer compared with placebo on serum K+ in HF patients.
Conditions
- Hyperkalemia
Interventions
PatiromerDrug
The starting dose of patiromer will be 1 packet/day and may be taken either with food or without food. Based upon the patiromer treatment algorithm patiromer may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, patiromer may be decreased to a minimum of 0 packets/day. Doses of patiromer will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
PlacebosDrug
The starting dose of placebo will be 1 packet/day and may be taken either with food or without food. Based upon the placebo treatment algorithm placebo may be increased by 1 packet per day in intervals of at least 1 week (± 3 days). For subjects who become hypokalemic, placebo may be decreased to a minimum of 0 packets/day. Doses of placebo will be 0 packets/day, 1 packet/day, 2 packets/day, and 3 packets/day (maximum dose).
Primary outcomes
What the sponsor says the trial is designed to measure.
- Changes in Serum K+ Levels From BaselineTime frame: Mean duration of exposure: 227.9 days for Patiromer and 234.5 days for Placebo
Locations
415 sites in 21 countries. Site status is shown where the registry gives one.
Investigator Site 11-080
Alexander City, Alabama
Investigator Site 11-041
Huntsville, Alabama
Investigator Site 11-153
Phoenix, Arizona
Investigator Site 11-097
Tucson, Arizona
Investigator Site 11-052
Bakersfield, California
Investigator Site 11-174
Fremont, California
Investigator Site 11-136
Fresno, California
Investigator Site 11-102
Huntington Beach, California
Investigator Site 11-162
La Jolla, California
Investigator Site 11-048
La Mesa, California
Investigator Site 11-111
Laguna Hills, California
Investigator Site 11-017
Long Beach, California
Investigator Site 11-128
Northridge, California
Investigator Site 11-035
Pasadena, California
Investigator Site 11-044
Sacramento, California
Investigator Site 11-135
San Diego, California
Investigator Site 11-086
San Diego, California
Investigator Site 11-112
Santa Ana, California
Investigator Site 11-101
Stockton, California
Investigator Site 11-047
Thousand Oaks, California
Investigator Site 11-057
Van Nuys, California
Investigator Site 11-058
West Hills, California
Investigator Site 11-095
Aurora, Colorado
Investigator Site 11-168
Altamonte Springs, Florida
Investigator Site 11-106
Boynton Beach, Florida
Investigator Site 11-028
Brandon, Florida
Investigator Site 11-003
Doral, Florida
Investigator Site 11-138
Gainesville, Florida
Investigator Site 11-164
Greenacres City, Florida
Investigator Site 11-078
Homestead, Florida
Investigator Site 11-004
Jacksonville, Florida
Investigator Site 11-179
Jacksonville, Florida
Investigator Site 11-122
Medley, Florida
Investigator Site 11-115
Miami, Florida
Investigator Site 11-125
Miami, Florida
Investigator Site 11-005
Miami, Florida
Research Site 11-001
Miami Lakes, Florida
Research Site 11-002
Miami Lakes, Florida
Investigator Site 11-032
North Miami Beach, Florida
Investigator Site 11-171
Orlando, Florida
Showing 40 of 415 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.